Euroopa Liit - eesti - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaktsiinid - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 ja 4. kasutada dengvaxia peab olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - rinnanäärmed - antineoplastilised ained - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Eesti - eesti - Ravimiamet

vetoquinol s.a. - amoksitsilliin+klavulaanhape - tablett - 40mg+10mg 120tk; 40mg+10mg 100tk; 40mg+10mg 200tk; 40mg+10mg 300tk; 40mg+10mg 150tk

Eesti - eesti - Ravimiamet

vetoquinol s.a. - amoksitsilliin+klavulaanhape - tablett - 200mg+50mg 10tk; 200mg+50mg 250tk; 200mg+50mg 50tk; 200mg+50mg 600tk; 200mg+50mg 300tk; 200mg+50mg 1000tk; 200mg+50mg 120tk; 200mg+50mg 20tk; 200mg+50mg 200tk; 200mg+50mg 750tk; 200mg+50mg 150tk; 200mg+50mg 400tk; 200mg+50mg 500tk; 200mg+50mg 100tk

Eesti - eesti - Ravimiamet

vetoquinol s.a. - amoksitsilliin+klavulaanhape - tablett - 400mg+100mg 1000tk; 400mg+100mg 750tk; 400mg+100mg 300tk; 400mg+100mg 600tk; 400mg+100mg 50tk; 400mg+100mg 120tk; 400mg+100mg 250tk; 400mg+100mg 100tk; 400mg+100mg 500tk; 400mg+100mg 200tk; 400mg+100mg 400tk; 400mg+100mg 10tk; 400mg+100mg 150tk

Eesti - eesti - Ravimiamet

vetoquinol s.a. - amoksitsilliin+klavulaanhape - tablett - 50mg+12,5mg 250tk; 50mg+12,5mg 100tk; 50mg+12,5mg 500tk

Eesti - eesti - Ravimiamet

richard bittner ag - taimsed preparaadid - suukaudne lahus - 500ml 1tk; 100ml 1tk; 250ml 1tk; 50ml 1tk

Eesti - eesti - Ravimiamet

orivas uab - kolekaltsiferool - suukaudne lahus - 50000rÜ 1ml 1ml 2tk; 50000rÜ 1ml 1ml 1tk; 50000rÜ 1ml 1ml 4tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - suguhormoonid ja immunoglobuliinid, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.